Journal of Clinical Oncology
Articles in this Issue
Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: A real-world clinical retrospective study.
e17094 Background: Effective treatment during the metastatic hormone-sensitive prostate cancer (mHSPC) stage is crucial for delaying disease progression....
Social determinants of health and timely chemotherapy initiation.
e13580 Background: Timely initiation of chemotherapy is critical for optimizing outcomes in gynecologic cancers. This study aimed to evaluate the effect o...
Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: A systematic review and network meta-analysis.
3075 Background: Targeted therapy with EGFR tyrosine-kinase inhibitors (TKIs) is the preferred first-line treatment for EGFR-mutated advanced non-small ce...
HER2 and HER3 expression in ovarian cancer: Evolution across chemotherapy exposure and implications for targeted therapies.
5552 Background: HER2 and HER3 are critical members of the ERBB receptor family, playing pivotal roles in tumorigenesis across multiple cancers, including...
Neoadjuvant immunotherapy in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma: A randomized, open label, phase II clinical trial.
6043 Background: The efficacy and safety of neoadjuvant immunotherapy (NAI) for resectable locally advanced head and neck squamous cell carcinoma (LAHNSCC...
Sociodemographic and clinicopathological factors affecting survival in young women: Real-world data from Brazil.
e17515 Background: Cervical cancer (CC) typically develops years after persistent HPV infection, yet its prevalence has been rising globally until recentl...
Prediction of post-treatment toxicities using the pre-treatment oral microbiome in the context of definitive chemoradiation for oropharyngeal cancer.
e18099 Background: Definitive chemoradiation for head and neck cancers is a common treatment with a high toxicity burden. There is an urgent need to ident...
Potential of ultrafine gold nanoparticles (AuNPs) as radio-contrast agent for early cancer detection.
e15062 Background: Gold nanoparticles have been employed in cancer imaging and treatment, offering advantages over iodine-based contrast agents, such as h...
Induction chemotherapy with or without toripalimab followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter, open-label, randomized, controlled, phase 2 trial.
6077 Background: Although nasopharyngeal carcinoma (NPC) treatment has entered the era of immunotherapy, the optimal treatment model for locoregionally ad...
Second-line outcomes in metastatic renal cell carcinoma: The role of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic factors after first-line immunotherapy.
4548 Background: IMDC prognostic factors are well established in metastatic renal cell carcinoma (mRCC) with both VEGFR inhibitor and immunotherapy-based...
Association of MRI biomarkers on survival in TNBC patients: A retrospective, multi-center cohort study.
e13155 Background: Triple-negative breast cancer (TNBC) is an aggressive subtype associated with heterogenous radiological and histopathological findings....
Survival trends and clinicopathological characteristics for patients with gastric cancer in a reference center in Mexico.
e16097 Background: Gastric cancer is common in Mexico, survival is low due to late-stage diagnosis and limited treatment access. We aimed to evaluate clin...
Peripheral blood cell-free DNA testing as a predictor for relapse post-allogeneic stem cell transplant for AML.
6555 Background: Allogeneic stem cell transplantation (allo-SCT) is a curative option for acute myelogenous leukemia (AML), but relapse is a challenge. Mo...
The SURVIVE HERoes study: Targeting molecular relapse in breast cancer—A secondary adjuvant intervention study of trastuzumab deruxtecan versus SOC treatment in patients with HER2-positive or HER2-low early breast cancer and ctDNA positivity after primary therapy.
TPS622 Background: Current research on circulating tumor DNA (ctDNA) in the adjuvant setting of early breast cancer (eBC) underscores its strong prognosti...
Artificial intelligence to predict outcome after [177Lu]Lu-PSMA for metastatic castration-resistant prostate cancer: Preliminary results from a multicentric prospective study.
e17077 Background: [ 177 Lu]Lu-PSMA-617 was approved for metastatic castration-res...
Donafenib plus TACE with or without PD-(L)1 inhibitors for the treatment of unresectable hepatocellular carcinoma: A multi-center retrospective study.
e16183 Background: Donafenib, a multikinase inhibitor, have shown superiority over sorafenib in improving OS and has favorable safety and tolerability in...
A medically tailored meal (MTM) delivery program to reduce nutritional decline and improve treatment tolerance in patients with colorectal cancer (CRC): A pilot study.
3564 Background: Colorectal cancer (CRC CA) is the 3 rd most common CA among US adults. Over 50% of CRC patients (pts) present wit...
Safety and pharmacokinetics of mevrometostat (M) in combination with enzalutamide (E) in patients with metastatic castration-resistant prostate cancer (mCRPC).
5046 Background: M is a potent and selective small molecule inhibitor of enhancer of zeste homolog 2 (EZH2). In the randomized dose-expansion part of a ph...
RETRACTED: Disability-adjusted life years from human papillomavirus–related oral cavity and pharynx cancers in US men, 2017–2021.
PD-1 blockade in combination with epigenetic therapy to antagonize tumor mesenchymal program and drive therapeutic efficacy in an esophageal adenocarcinoma model.
e16159 Background: Immune checkpoint blockade (ICB) alone or in combination with chemotherapy has demonstrated a modest survival benefit in gastroesophage...
CODEX2: A novel scoring system for CDX2 loss in colon cancer—Unraveling prognostic insights and therapeutic opportunities.
e15661 Background: CDX2 protein loss in colorectal cancer (CRC) correlates with poor prognosis, yet the mechanisms driving its loss and associated molecul...
Prognostic insights in skin melanoma: A study of differential diagnostic tissue markers.
e21576 Background: Cutaneous melanoma is the most aggressive form of skin cancer, necessitating reliable prognostic markers for risk stratification. Despi...
The impact of the use of hypomethylating agents prior to reduced intensity conditioning allogeneic bone marrow transplant among patients with MDS.
6557 Background: Allogeneic transplantation is the only potential cure for patients with myelodysplastic syndrome (MDS). It is unclear whether cytoreducti...
Patritumab deruxtecan (HER3-DXd) in resistant <i>EGFR</i> -mutated ( <i>EGFR</i> m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.
8506 Background: After disease progression on a 3rd-gen (3G) EGFR TKI for advanced EGFR m NSCLC, available therapies provide limit...
Enabling national identification of lung cancer screening eligibility with large language models.
e13613 Background: Lung cancer (LC) is the leading cause of cancer-related death, yet screening uptake among eligible individuals is under 20%. Incomplete...